New insight into blood pressure control may explain diabetes drugs' side benefit

March 04, 2008

Drugs known as thiazolidinediones (TZDs), which are used to treat type 2 diabetes, seem to come with an added side benefit: They lower blood pressure. Now, researchers reporting in the March issue of Cell Metabolism, a publication of Cell Press, provide new evidence as to why.

The researchers show that so-called peroxisome proliferator-activated receptor Ó (PPARÓ)--a molecule that stands at the crossroads of metabolic and cardiovascular diseases and is the target of TZDs--plays an unanticipated protective role in the blood vessel wall.

"The incidence of obesity and diabetes and their cardiovascular consequences has reached epidemic proportions, justifying the enormous effort to identify pathways and molecules involved in their pathogenesis," said Curt Sigmund of the University of Iowa. "This study provides evidence for a pivotal role of smooth muscle PPARÓ in the regulation of vascular structure and function and provides a molecular explanation for some of the beneficial cardiovascular effects of TZD drugs."

The importance of PPARÓ was made clear when scientists found it to be the target of insulin-sensitizing TZDs, the researchers noted. Several studies also indicated that people taking TZDs for diabetes tended toward lower blood pressure and signs of other cardiovascular improvements. But that view was recently challenged by a still controversial study suggesting that the risk of adverse cardiovascular events, including heart attack and death, may actually rise in patients taking the TZD rosiglitazone (Avandia), added Sigmund's group. "Accordingly," they wrote, "there is an urgent need not only to assess the beneficial and consequential effects of TZDs but also to understand the fundamental mechanisms controlling the metabolic and cardiovascular function of PPARÓ itself."

To test PPARÓ's blood vessel role, the researchers developed mice lacking the gene encoding PPARÓ in smooth vascular muscle. These animals showed changes in their blood vessels, characterized by a failure to vasodilate, or expand, in response to nitric oxide. The animals also developed high blood pressure and other "striking alterations" in the structure and function of their vasculature. "If this protein is deactivated, it appears that the protective pathways can't be activated," Sigmund said.

As for studies suggesting detrimental effects of TZDs, Sigmund said, like most things, balance in this protein is probably key. "There will be interest in developing variations of these molecules that keep all the 'goodies' and get rid of the bad," he said.
-end-
The researchers include Carmen M. Halabi, Andreas M. Beyer, Willem J. de Lange, Henry L. Keen, Gary L. Baumbach, Frank M. Faraci, and Curt D. Sigmund, all of the Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA.

Cell Press

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.